Drug Profile
Research programme: antibacterials targeting Bordetella pertussis - ALERT B&C Corp
Alternative Names: Research programme: antibacterials targeting Bordetella pertussis - Genomics OneLatest Information Update: 25 Aug 2006
Price :
$50
*
At a glance
- Originator ALERT B&C Corporation
- Developer ALERT B&C Corporation; University of British Columbia
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 16 Dec 2002 This programme is still in active development
- 10 Aug 2000 Preclinical development for Bacterial infections in Canada (Unknown route)